Connection

Peng Xia to Neovascularization, Pathologic

Back to Details
This is a "connection" page, showing publications Peng Xia has written about Neovascularization, Pathologic.
Peng Xia
Connection Strength
0.133
Neovascularization, Pathologic
  1. Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models. Mol Cancer Ther. 2018 04; 17(4):751-762.
    View in: PubMed
    Score: 0.133
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.